The GeneXpert diagnostic testing technology from the US-based corporation Cepheid has revolutionised rapid, accurate diagnosis of tuberculosis (TB) since entering the market in 2010. Yet, due to the high cost of the GeneXpert instrument and its tests, most high TB-burden countries are not able to scale up testing for all people who need diagnosis.
In this video, MSF staff working in places where people have been severely affected by COVID-19 speak out about their experiences, and how the lack of access to COVID-19 vaccines has impacted the communities where they work.
